Tag Archive for: Cancer

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

/in

Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, today announced the signing of a global supply agreement for the medical radionuclides […]

Read more

Cure51 launches NHS-approved study with Cambridge University Hospitals and seven other leading UK oncology institutions to unlock cancer survival secrets

/in

Pioneering Rosalind study aims to transform cancer treatment with insights from ‘super-responder’ patients Tumor samples from over 1,000 cancer survivors across three aggressive types will be analyzed for genetics and biomarkers Findings will enrich Cure51’s multi-omics database to advance new biology and precision medicine tools Paris, France, 18 November 2024 – Cure51, a techbio company […]

Read more

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

/in

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expression data shows upregulation of innate immunity pathways Tumor regressions observed at all dose levels, 60-200 mg TIW 11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

/in

David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, […]

Read more

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

/in

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical development Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used 100% survival with a single dose of 30 kBq 225Ac-satoreotide but […]

Read more
© Optimum Strategic Communications.